Proprietary AI analyst is now available

3D Medicines Valuation Multiples

Discover revenue and EBITDA valuation multiples for 3D Medicines and similar public comparables like Agronomics, Semnur Pharmaceuticals, Eurofins-Cerep, ImmuCell and more.

3D Medicines Overview

About 3D Medicines

3D Medicines Inc is a commercial-stage biopharmaceutical company engaged in the research and development of oncology therapies for cancer patients, especially those who require long-term care. It develops differentiated immuno-oncology drugs, helping cancer patients live with prolonged survival time and quality of life. It generates all of its revenue from China.


Founded

2018

HQ

China

Employees

191

Financials (FY)

Revenue: $53M
EBITDA: ($24M)

EV

$46M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

3D Medicines Financials

3D Medicines reported last fiscal year revenue of $53M and negative EBITDA of ($24M).

In the same fiscal year, 3D Medicines generated $48M in gross profit, ($24M) in EBITDA losses, and had net loss of ($26M).


3D Medicines P&L

In the most recent fiscal year, 3D Medicines reported revenue of $53M and EBITDA of ($24M).

3D Medicines is unprofitable as of last fiscal year, with gross margin of 92%, EBITDA margin of (46%), and net margin of (50%).

See analyst estimates for 3D Medicines
Last FY202320242025202620272028
Revenue$53M$94M$66M$53M
Gross Profit$48M$87M$60M$48M
Gross Margin92%92%92%92%
EBITDA($24M)($78M)($24M)($24M)
EBITDA Margin(46%)(83%)(37%)(46%)
EBIT Margin(21%)(66%)(18%)(21%)
Net Profit($26M)($78M)($27M)($26M)
Net Margin(50%)(83%)(41%)(50%)

Financial data powered by Morningstar, Inc.

3D Medicines Stock Performance

3D Medicines has current market cap of $88M, and enterprise value of $46M.

Market Cap Evolution


3D Medicines' stock price is $0.36.

3D Medicines share price decreased by 17.9% in the last 30 days.

3D Medicines has an EPS (earnings per share) of $-0.11.

See more trading valuation data for 3D Medicines
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$46M$88M-1.4%-17.9%--$-0.11

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

3D Medicines Valuation Multiples

3D Medicines trades at 0.9x EV/Revenue multiple, and (1.9x) EV/EBITDA.

See NTM and 2027E valuation multiples for 3D Medicines

3D Medicines Financial Valuation Multiples

As of June 23, 2026, 3D Medicines has market cap of $88M and EV of $46M.

3D Medicines has a P/E ratio of (3.4x).

Last FY202320242025202620272028
EV/Revenue0.9x0.5x0.7x0.9x
EV/EBITDA(1.9x)(0.6x)(1.9x)(1.9x)
EV/EBIT(4.2x)(0.7x)(3.9x)(4.2x)
EV/Gross Profit0.9x0.5x0.8x0.9x
P/E(3.4x)(1.1x)(3.3x)(3.4x)
EV/FCF(1.9x)(2.1x)(1.2x)(1.9x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified 3D Medicines Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

3D Medicines Margins & Growth Rates

In the most recent fiscal year, 3D Medicines reported gross margin of 92%, EBITDA margin of (46%), and net margin of (50%).

See estimated margins and future growth rates for 3D Medicines

3D Medicines Margins

Last FY20242025202720282029
Gross Margin92%92%92%
EBITDA Margin(46%)(37%)(46%)
EBIT Margin(21%)(18%)(21%)
Net Margin(50%)(41%)(50%)
FCF Margin(45%)(57%)(45%)

3D Medicines Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth(30%)(20%)
Gross Profit Growth(30%)(20%)
EBITDA Growth(69%)(0%)
EBIT Growth(81%)(7%)
Net Profit Growth(65%)(3%)
FCF Growth70%(38%)

Data powered by FactSet, Inc. and Morningstar, Inc.

3D Medicines Operational KPIs

3D Medicines' revenue per employee in the last FY averaged $0.3M, while opex per employee averaged $0.3M for the same period.

Access forward-looking KPIs for 3D Medicines
Last FY202320242025202620272028
Revenue per Employee$0.3M---
Opex per Employee$0.3M---
S&M Expenses to Revenue52%60%53%52%
G&A Expenses to Revenue20%34%18%20%
R&D Expenses to Revenue44%67%41%44%
Opex to Revenue113%159%110%113%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

3D Medicines Competitors

3D Medicines competitors include Agronomics, Semnur Pharmaceuticals, Eurofins-Cerep, ImmuCell, Cardiff Oncology, Actinogen Medical, SynAct Pharma, Rani Therapeutics, Ryvu Therapeutics and Aardvark Therapeutics.

Most 3D Medicines public comparables operate across Biopharmaceuticals, Diagnostics & Genomics, BioTech and DeepTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Agronomics(5.4x)-(2.4x)-
Semnur Pharmaceuticals--(0.7x)-
Eurofins-Cerep1.4x-8.7x-
ImmuCell3.4x-44.1x-
Cardiff Oncology72.7x101.1x(0.9x)-
Actinogen Medical-10.9x-(7.4x)
SynAct Pharma--(6.6x)(18.4x)
Rani Therapeutics29.1x16.8x(1.3x)-

This data is available for Pro users. Sign up to see all 3D Medicines competitors and their valuation data.

Start Free Trial

3D Medicines VC Funding History

Before going public, 3D Medicines raised $505M in total equity funding, across 4 rounds.


3D Medicines Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Oct-20Undisclosed stageCPE; Sangel Capital; Jimin Kexin Pharmaceutical; Shandong Transportation Industry Development Fund; Ruiyi Investment; Lucion; Haier; Tsing Capital; Shanghai Pudong Science and Technology Investment; Lan Shang Capital; China Capital Investment Group$223M--
Oct-20Undisclosed stageChina Capital Management; Tigermed; EFung Capital; Ruiyi Investment; Hyde Capital; Zhigang Zheng; Ruixin Shunying Investment Fund$140M-3D Medicines, a Chinese precision medicine developer focused on tumor immunotherapy, completed a $140 million equity financing round in early October 2020, co-led by China Capital Management and EFung Capital, following the spin-off of its diagnostics unit 3DMed Diagnostic two years prior. This was described as the precision medicine R&D unit's first round post-spin-off, with investors aligning with the specified list including Hyde Capital, Ruixin Shunying Investment Fund, Ruiyi Investment, Tigermed, and Zhigang Zheng. 3DMed Diagnostic, the spun-off molecular diagnostics firm, separately raised 1.5 billion yuan ($224 million) in its second equity round around October 20, 2020, led by other investors, primarily for R&D in next-generation sequencing equipment, IVDs, overseas expansion, and commercialization. Its prior January 2020 round raised 280 million yuan ($41.8 million) led by China Resources Pharmaceutical Industry Investment Fund. China's precision medicine market generated over $4.9 billion in revenue in 2018, projected to grow at a 12.82% CAGR through 2029, driven by preventive medicine shifts, government initiatives, cost reductions, and sequencing advancements. Later reports show 3D Medicines achieving RMB634.9 million in revenue from Envafolimab (恩维达®) sales in 2023, up 11.9% year-on-year, with marketing approval in mainland China in November 2021 and Macao in January 2024, alongside a pipeline of 12 drugs or candidates as of December 31, 2023, and cash reserves of RMB666.5 million sufficient for two years of operations.
Jan-20Undisclosed stageGuangzhou Guofa Venture Capital; Shanghai Zhangjiang Technology Venture Capital; Shandong Transportation Industry Development Fund; Lucion; China Equity; China Resources Pharmaceutical Industry Investment Fund$41M--
Nov-17Undisclosed stageChina Reform Fund Management; China Equity$101M--

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About 3D Medicines

When was 3D Medicines founded?3D Medicines was founded in 2018.
Where is 3D Medicines headquartered?3D Medicines is headquartered in China.
How many employees does 3D Medicines have?As of today, 3D Medicines has over 191 employees.
Is 3D Medicines publicly listed?Yes, 3D Medicines is a public company listed on HKEX.
What is the stock symbol of 3D Medicines?3D Medicines trades under 01244 ticker.
When did 3D Medicines go public?3D Medicines went public in 2022.
Who are competitors of 3D Medicines?3D Medicines main competitors include Agronomics, Semnur Pharmaceuticals, Eurofins-Cerep, ImmuCell, Cardiff Oncology, Actinogen Medical, SynAct Pharma, Rani Therapeutics, Ryvu Therapeutics, Aardvark Therapeutics.
What is the current market cap of 3D Medicines?3D Medicines' current market cap is $88M.
What is the current revenue of 3D Medicines?3D Medicines' last fiscal year revenue is $53M.
What is the current EV/Revenue multiple of 3D Medicines?Current revenue multiple of 3D Medicines is 0.9x.
Is 3D Medicines profitable?No, 3D Medicines is not profitable.
How many companies 3D Medicines has acquired to date?3D Medicines hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies 3D Medicines has invested to date?3D Medicines hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to 3D Medicines

Lists including 3D Medicines

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial